Dermatomyositis Causes and Symptoms – Overview
The report gives far reaching data on the therapeutics a work in progress for Dermatomyositis, complete with examination by phase of improvement, medication target, instrument of activity (MoA), course of organization (RoA) and atom sort. The report likewise covers the spellbinding pharmacological activity of the therapeutics, its complete innovative work history and most recent news and public statements. Furthermore, the report gives a diagram of key players required in helpful improvement for Dermatomyositis and components lethargic and stopped tasks.
The report gives far reaching data on the therapeutics a work in progress for Dermatomyositis, complete with examination by phase of improvement, medication target, instrument of activity (MoA), course of organization (RoA) and atom sort. The report likewise covers the spellbinding pharmacological activity of the therapeutics, its complete innovative work history and most recent news and public statements. Furthermore, the report gives a diagram of key players required in helpful improvement for Dermatomyositis and components lethargic and stopped tasks.
- TAGS
- dermatomyositis-news
- dermatomyositis-rash
- relapsing-polychondritis
- heliotrope-rash
- scleroderma
- fibromyalgia
- polymyositis
- connective-tissue-diseases
- disorders-of-fascia
- inflammations
- autoimmune-diseases
- dermatomyositis-prognosis
- lung-disease-radiology
- dermatomyositis-lung-radiology
- dermatomyositis-symptoms
- dermatomyositis-radiology
- dermatomyositis-signs
- dermatomyositis-causes
- dermatomyositis-treatment
- dermatomyositis
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Dermatomyositis</strong> - Pipeline Review H1<br />
2016<br />
Telephone: +1 (800) 910-6452<br />
Mail at: sales@researchbeam.com
Report <strong>Overview</strong><br />
‘<strong>Dermatomyositis</strong> - Pipeline Review, H1 2016’, provides an overview of the <strong>Dermatomyositis</strong> pipeline<br />
l<strong>and</strong>scape.<br />
The report provides comprehensive information on the therapeutics under development for<br />
<strong>Dermatomyositis</strong>, complete with analysis by stage of development, drug target, mechanism of action<br />
(MoA), route of administration (RoA) <strong>and</strong> molecule type. The report also covers the descriptive<br />
pharmacological action of the therapeutics, its complete research <strong>and</strong> development history <strong>and</strong> latest<br />
news <strong>and</strong> press releases. Additionally, the report provides an overview of key players involved in<br />
therapeutic development for <strong>Dermatomyositis</strong> <strong>and</strong> features dormant <strong>and</strong> discontinued projects.<br />
This report features investigational drugs from across globe covering over 20 therapy areas <strong>and</strong> nearly<br />
3,000 indications. The report is built using data <strong>and</strong> information sourced from proprietary databases,<br />
company/university websites, clinical trial registries, conferences, SEC filings, investor presentations <strong>and</strong><br />
featured press releases from company/university sites <strong>and</strong> industry-specific third party sources. Drug<br />
profiles featured in the report undergoes periodic review following a stringent set of processes to ensure<br />
that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking<br />
processes ensure that the most recent developments are captured on a real time basis.<br />
The report helps in identifying <strong>and</strong> tracking emerging players in the market <strong>and</strong> their portfolios, enhances<br />
decision making capabilities <strong>and</strong> helps to create effective counter strategies to gain competitive<br />
advantage.<br />
Strategic Focus Report: http://www.researchbeam.com/dermatomyositis-pipeline-review-h1-2016-<br />
market
Report <strong>Overview</strong><br />
Scope<br />
- The report provides a snapshot of the global therapeutic l<strong>and</strong>scape of <strong>Dermatomyositis</strong><br />
- The report reviews pipeline therapeutics for <strong>Dermatomyositis</strong> by companies <strong>and</strong> universities/research<br />
institutes based on information derived from company <strong>and</strong> industry-specific sources<br />
- The report covers pipeline products based on various stages of development ranging from preregistration<br />
till discovery <strong>and</strong> undisclosed stages<br />
- The report features descriptive drug profiles for the pipeline products which includes, product<br />
description, descriptive MoA, R&D brief, licensing <strong>and</strong> collaboration details & other developmental<br />
activities<br />
Reasons to buy<br />
- Gain strategically significant competitor information, analysis, <strong>and</strong> insights to formulate effective R&D<br />
strategies<br />
- Identify emerging players with potentially strong product portfolio <strong>and</strong> create effective counterstrategies<br />
to gain competitive advantage<br />
- Identify <strong>and</strong> underst<strong>and</strong> important <strong>and</strong> diverse types of therapeutics under development for<br />
<strong>Dermatomyositis</strong><br />
- Develop strategic initiatives by underst<strong>and</strong>ing the focus areas of leading companies<br />
- Plan mergers <strong>and</strong> acquisitions effectively by identifying key players <strong>and</strong> it’s most promising pipeline<br />
therapeutics
Table of Contents<br />
Table of Contents 2<br />
List of Tables 4<br />
List of Figures 4<br />
Introduction 5<br />
Global Markets Direct Report Coverage 5<br />
<strong>Dermatomyositis</strong> <strong>Overview</strong> 6<br />
Therapeutics Development 7<br />
Pipeline Products for <strong>Dermatomyositis</strong> - <strong>Overview</strong> 7<br />
<strong>Dermatomyositis</strong> - Therapeutics under Development by Companies 8<br />
<strong>Dermatomyositis</strong> - Pipeline Products Glance 9<br />
Clinical Stage Products 9<br />
Early Stage Products 10<br />
<strong>Dermatomyositis</strong> - Products under Development by Companies 11<br />
<strong>Dermatomyositis</strong> - Companies Involved in Therapeutics Development 12<br />
F. Hoffmann-La Roche Ltd. 12<br />
Hope Pharmaceuticals, Inc. 13<br />
Idera Pharmaceuticals, Inc. 14<br />
MedImmune, LLC 15<br />
Neovacs SA 16<br />
Novartis AG 17<br />
<strong>Dermatomyositis</strong> - Therapeutics Assessment 18<br />
Assessment by Monotherapy Products 18<br />
Assessment by Target 19
Report Ordering<br />
Report Name:<br />
<strong>Dermatomyositis</strong> - Pipeline Review H1 2016<br />
Product Price<br />
User<br />
Price<br />
Single User US $ 1700<br />
Site User US $ 4000<br />
Global User US $ 6000<br />
To View Sample or Purchase Report
Contact Us<br />
FOR MORE DETAILS<br />
Visit us at :<br />
http://www.researchbeam.com/dermatomyositis-pipeline-review-h1-2016-market<br />
Stay With Us At:<br />
TELEPHONE: +1 (800) 910-6452<br />
DIRECT: +1 (503) 894-6022<br />
E-MAIL: sales@researchbeam.com<br />
5933 NE Win Sivers Drive,<br />
#205, Portl<strong>and</strong>, OR 97220<br />
United States
Change language